Try our Advanced Search for more refined results
April 03, 2013
In re: ADDERALL XR ANTITRUST
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
June 09, 2014
2nd Circ. Affirms Dismissal Of Adderall Pay-For-Delay Suit
The Second Circuit on Monday found that Shire LLC didn't block generic competition for its attention-deficit-hyperactivity drug Adderall XR, saying a lower court was correct to dismiss a consolidated class action because Shire's patent licensing agreements didn't raise an antitrust issue.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login